Clinical Trial: Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Castration-resistant Prostate Cancer
Study Type: INTERVENTIONAL
Official Title: A Multicenter, Non-randomized, Open-label, and Dose-escalation Phase I Study to Evaluate the Safety of Prodencel Treatment in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Brief Summary:
This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Read more